Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation.
Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation.
复制标题
DOI：
--
复制
发表时间：
2014-12
影响因子：
2
通讯作者：
H. Hayashi;R. Kobayashi;A. Suzuki;M. Ishihara;Nobuhiko Nakamura;J. Kitagawa;N. Kanemura;S. Kasahara;K. Kitaichi;T. Hara;H. Tsurumi;H. Moriwaki;Y. Itoh
中科院分区：
文献类型：
--
作者：
H. Hayashi;R. Kobayashi;A. Suzuki;M. Ishihara;Nobuhiko Nakamura;J. Kitagawa;N. Kanemura;S. Kasahara;K. Kitaichi;T. Hara;H. Tsurumi;H. Moriwaki;Y. Itoh
我们以前曾报道，Polaprezinc在海藻酸钠混悬液（P-AG）抑制头颈癌患者放化疗引起的口腔粘膜炎的发生率。本研究旨在调查是否P-AG预防口腔粘膜炎的所有患者（36例）接受大剂量化疗和放疗后造血干细胞移植（HSCT）的血液恶性肿瘤。与对照组相比，P-AG显著降低了中度至重度口腔粘膜炎的发生率（≥ 2级为20% vs 82%，p<0.01; ≥ 3级为0% vs 45%，p<0.01）。P-AG还显著缓解了与口腔粘膜炎相关的疼痛（p=0.004），从而减少了镇痛剂的使用（28% vs 73%，p=0.025）。P-AG有降低口干和味觉障碍发生率的趋势，但不显著。P-AG对其他不良事件的发生率、肿瘤缓解率和生存率无影响。因此，发现P-AG在预防口腔粘膜炎方面非常有效，不仅由头颈癌的放射化学疗法引起，而且由高剂量化学疗法和放射疗法随后的HSCT引起。
We have previously reported that polaprezinc in sodium alginate suspension (P-AG) inhibited the incidence of oral mucositis induced by radiochemotherapy in patients with head and neck cancer. The present study was designed to investigate whether P-AG prevents oral mucositis in all patients (36 patients) with hematological malignancy receiving high-dose chemotherapy and radiotherapy followed by hematopoietic stem cell transplantation (HSCT). P-AG dramatically reduced the incidence of moderate-to-severe oral mucositis as compared to the control group treated with azulene gargle (20% versus 82% for grade ≥ 2, p<0.01; 0% versus 45% for grade ≥ 3, p<0.01). Pain associated with oral mucositis was also significantly (p=0.004) relieved by P-AG, resulting in a reduction in the use of analgesic agents (28% versus 73%, p=0.025). The incidence of xerostomia and taste disturbance tended to be lowered but not significantly by P-AG. On the other hand, P-AG had no influence on the incidence of other adverse events, tumor remission rate or the survival rate. Therefore, P-AG was found to be highly effective in preventing oral mucositis induced not only by radiochemotherapy for head and neck cancer but also by high-dose chemotherapy and radiotherapy followed by HSCT.